Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Food and Drug Administration (FDA)
Biotech
FDA delays Belite’s eye disease pill decision by 3 months
The U.S. regulator is pushing the decision for Belite’s oral Stargardt disease type 1 drug candidate from its original February action date.
Michael Gibney
Nov 20, 2026 9:08am
Teva loses R&D head amid innovation revamp—Chutes & Ladders
Nov 20, 2026 8:30am
FDA’s rare disease framework aims to ‘stand the test of time’
Oct 28, 2026 3:16pm
CBER Director Mikhail feels FDA is ‘getting back to stability’
Oct 21, 2026 8:00am
How NIH’s Kleinstreuer reduces animal tests without ‘backlash’
Oct 6, 2026 8:00am
Merck and Daiichi pull lung cancer filing after FDA pushback
Sep 28, 2026 4:30am